Seeking Alpha
 

Cyclacel Pharmaceuticals, Inc. (CYCC)

- NASDAQ
  • Wed, Mar. 25, 7:00 AM
    • Cyclacel Pharmaceuticals (CYCC -1%) Q4 results: Revenues: $0.2M (-33.3%); R&D Expense: $4.4M (+76.0%); SG&A: $1.6M (-11.1%); Operating Loss: ($5.8M) (-45.0%); Net Loss: ($4.8M) (-33.3%); Loss Per Share: ($0.21) (-5.0%).
    • FY2014 results: Revenues: $1.7M (+54.5%); R&D Expense: $18.3M (+61.9%); SG&A: $5.9M (-24.4%); Operating Loss: ($22.4M) (-24.4%); Net Loss: ($19.4M) (-90.2%); Loss Per Share: ($0.89) (+31.0%); Quick Assets: $24.2M (-22.2%).
    • No guidance given.
    | Comment!
  • Tue, Mar. 24, 4:08 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q4 EPS of -$0.21 beats by $0.05.
    • Cash and cash equivalents of $24.19M.
    • Press Release
    | Comment!
  • Nov. 12, 2014, 12:32 PM
    • Cyclacel Pharmaceuticals (CYCC -2.6%) Q3 results: Revenues: $0.7M (+133.3%); Operating Expenses: $6.4M (+4.9%); Operating Loss: ($5.8M) (unch); Net Loss: ($5M) (+12.3%); Loss Per Share: ($0.22) (-31.3%); Quick Assets: $26.7M (-14.1%).
    • No guidance given.
    | Comment!
  • Nov. 11, 2014, 4:09 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q3 EPS of -$0.22 beats by $0.04.
    • Revenue of $0.74M (+137.9% Y/Y).
    • Cash and equivalents of $26.7M.
    • Press Release
    | 2 Comments
  • Nov. 4, 2014, 12:09 PM
    • Cyclacel Pharmaceuticals (CYCC -0.9%) will report Q3 results on November 11 after the close. The conference call will begin at 4:30 pm ET.
    • Consensus view is a loss of ($0.26) per share on revenues of $80K.
    | Comment!
  • Aug. 13, 2014, 1:02 PM
    • Cyclacel Pharmaceuticals (CYCC -1.5%) Q2 results: Revenues: $0.4M (+34.8%); Operating Expenses: $5.9M (+34.2%); Operating Loss: ($5.6M) (-34.2%); Net Loss: ($4.8M) (-326.0%); Loss Per Share: ($0.22) (-220.0%); Quick Assets: $31.1M (-6.9%).
    • No financial guidance given.
    | 1 Comment
  • Aug. 12, 2014, 4:14 PM
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC): Q2 EPS of -$0.22 beats by $0.08.
    • Revenue of $0.36M (+38.5% Y/Y)
    • Press Release
    | Comment!
  • May. 13, 2014, 4:54 PM
    • Cyclacel Pharmaceuticals (CYCC): Q1 EPS of -$0.25 beats by $0.01.
    • Shares +2.5% AH.
    • Press Release
    | Comment!
  • Mar. 25, 2014, 4:25 PM
    • Cyclacel Pharmaceuticals (CYCC): Q4 EPS of -$0.19 beats by $0.14.
    • Revenue of $299K
    • Press Release
    | Comment!
  • Nov. 12, 2013, 5:20 PM
    • Cyclacel Pharmaceuticals (CYCC) announces Q3 results and says it expects its $35M in cash to be enough to last through the completion of SEAMLESS (that's sapacitabine in AML), which is near the 50% enrollment mark.
    • The company also reminds investors that primary outcomes from sapacitabine in MDS (Phase 2) will be reported at ASH.
    • R&D for the quarter comes in at $4.6M, up sharply thanks (in part) to manufacturing costs for SEAMLESS.
    • CYCC also plans (in the next 12 months) to: "Announce registration-directed, clinical development plan for sapacitabine in MDS after treatment failure of hypomethylating agents [and] report updated data from the Phase 1 study of sapacitabine and seliciclib in patients with advanced solid tumors, including BRCA carriers." (PR)
    | Comment!
  • Nov. 12, 2013, 5:02 PM
    • Cyclacel Pharmaceuticals (CYCC): FQ3 EPS of -$0.32 misses by $0.01.
    • Revenue of $309.0M . (PR)
    | Comment!
  • Aug. 14, 2013, 6:56 PM
    • Cyclacel Pharmaceuticals (CYCC) Q2 slips on a per share basis as losses come in higher than anticipated.
    • Q2 EPS of ($0.10), versus ($0.45) reported last year.
    • Total revenue of $264K compared to $26K in prior year.
    • R&D expenses were $2.6M compared to $1.7M for the same period in 2012, primarily due to clinical trial and manufacturing costs.
    • Cash and cash equivalents totaled $33.7M.
    • Shares -4.4% AH.
    | Comment!
  • Mar. 27, 2013, 4:33 PM
    Cyclacel Pharmaceuticals (CYCC): Q4 EPS of -$0.59. Shares +5.4% AH. (PR)
    | Comment!
Visit Seeking Alpha's
CYCC vs. ETF Alternatives
Company Description
Cyclacel Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States